Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Yu K, Hyun N, Fetterman B, Lorey T, Raine-Bennett TR, Zhang H, Stamps RE, Poitras NE, Wheeler W, Befano B, Gage JC, Castle PE, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Apr 11. doi: 10.1093/jnci/djy044. [Epub ahead of print]

PMID:
29659930
2.

High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections.

Chan RC, Leung RH, Posadas A, Lorey TS, Shaw AJ.

Biomed Rep. 2018 Mar;8(3):224-234. doi: 10.3892/br.2018.1047. Epub 2018 Jan 24.

3.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

4.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01910-17. doi: 10.1128/JCM.01910-17. Print 2018 May.

PMID:
29491018
5.

Interventions to Improve Follow-Up of Laboratory Test Results Pending at Discharge: A Systematic Review.

Whitehead NS, Williams L, Meleth S, Kennedy S, Epner P, Singh H, Wooldridge K, Dalal AK, Walz SE, Lorey T, Graber ML.

J Hosp Med. 2018 Feb 28. doi: 10.12788/jhm.2944. [Epub ahead of print]

PMID:
29489926
6.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

PMID:
29437696
7.

Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Castle PE, Wentzensen N, Burk RD.

Clin Cancer Res. 2018 May 1;24(9):2194-2202. doi: 10.1158/1078-0432.CCR-17-3251. Epub 2018 Feb 2.

PMID:
29420222
8.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

PMID:
29356609
9.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
10.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

11.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
12.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

PMID:
29145648
13.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

14.

HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M.

Cell. 2017 Sep 7;170(6):1164-1174.e6. doi: 10.1016/j.cell.2017.08.001.

PMID:
28886384
15.

Improving American Healthcare Through "Clinical Lab 2.0": A Project Santa Fe Report.

Crawford JM, Shotorbani K, Sharma G, Crossey M, Kothari T, Lorey TS, Prichard JW, Wilkerson M, Fisher N.

Acad Pathol. 2017 Apr 18;4:2374289517701067. doi: 10.1177/2374289517701067. eCollection 2017 Jan-Dec.

16.

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA.

Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.

PMID:
28660629
17.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
18.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, Xie Y, Miachon LS, Dean M.

J Clin Microbiol. 2017 Aug;55(8):2348-2355. doi: 10.1128/JCM.00492-17. Epub 2017 May 17.

19.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

20.

A cohort study of cervical screening using partial HPV typing and cytology triage.

Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC, Cheung LC, Befano B, Poitras N, Lorey T, Castle PE, Wentzensen N.

Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

21.

HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women.

Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, Zhang X, Yu K, Yang Q, Mitchell J, Roberson D, Bass S, Xiao Y, Burdett L, Raine-Bennett T, Lorey T, Castle PE, Burk RD, Schiffman M.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw100. doi: 10.1093/jnci/djw100. Print 2016 Sep.

22.

Angiosarcoma arising in association with vascular Dacron grafts and orthopedic joint prostheses: clinicopathologic, immunohistochemical, and molecular study.

Agaimy A, Ben-Izhak O, Lorey T, Scharpf M, Rubin BP.

Ann Diagn Pathol. 2016 Apr;21:21-8. doi: 10.1016/j.anndiagpath.2016.01.002. Epub 2016 Jan 11. Review.

PMID:
27040926
23.

Response.

Wentzensen N, Fetterman B, Castle P, Schiffman M, Wood S, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W.

J Natl Cancer Inst. 2015 Dec 27;108(2). pii: djv390. doi: 10.1093/jnci/djv390. Print 2016 Feb. No abstract available.

24.

Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection.

Cullen M, Boland JF, Schiffman M, Zhang X, Wentzensen N, Yang Q, Chen Z, Yu K, Mitchell J, Roberson D, Bass S, Burdette L, Machado M, Ravichandran S, Luke B, Machiela MJ, Andersen M, Osentoski M, Laptewicz M, Wacholder S, Feldman A, Raine-Bennett T, Lorey T, Castle PE, Yeager M, Burk RD, Mirabello L.

Papillomavirus Res. 2015 Dec 1;1:3-11.

25.

Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.

Agaimy A, Specht K, Stoehr R, Lorey T, Märkl B, Niedobitek G, Straub M, Hager T, Reis AC, Schilling B, Schneider-Stock R, Hartmann A, Mentzel T.

Am J Surg Pathol. 2016 Feb;40(2):181-91. doi: 10.1097/PAS.0000000000000527.

PMID:
26448190
26.

Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.

Mills JR, Greene DN, Bainton J, Lorey TS, Baumann NA.

Clin Chem. 2015 Oct;61(10):1241-4. doi: 10.1373/clinchem.2014.228247. No abstract available.

27.

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W.

J Natl Cancer Inst. 2015 Sep 15;107(12):djv257. doi: 10.1093/jnci/djv257. Print 2015 Dec.

28.

Challenges in harmonizing integrated healthcare network laboratories: multi-center evaluation of the hCG5 assay.

Greene DN, Baird GS, Kwong SL, Lorey TS, Holmes DT.

Clin Biochem. 2016 Jan;49(1-2):105-10. doi: 10.1016/j.clinbiochem.2015.08.019. Epub 2015 Aug 19.

PMID:
26297115
29.

Age, sex, and racial influences on the Beckman Coulter AccuTnI+3 99th percentile.

Greene DN, Leong TK, Collinson PO, Kamer SM, Huang K, Lorey TS, Go AS.

Clin Chim Acta. 2015 Apr 15;444:149-53. doi: 10.1016/j.cca.2015.02.005. Epub 2015 Feb 12.

PMID:
25684454
30.

Response.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Dec 26;107(1):390. doi: 10.1093/jnci/dju390. Print 2015 Jan. No abstract available.

31.

Challenges in harmonizing integrated healthcare network laboratories: Multi-center evaluation of the AccuTnI+3 troponin assay.

Greene DN, Holmes DT, Liang J, Kwong SL, Lorey TS, Petrie MS.

Clin Biochem. 2015 Mar;48(4-5):268-74. doi: 10.1016/j.clinbiochem.2014.11.009. Epub 2014 Nov 20.

PMID:
25464016
32.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

33.

Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.

Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, Stiemerling E, Poitras N, Lorey T, Kinney W.

Cancer Cytopathol. 2014 Dec;122(12):914-20. doi: 10.1002/cncy.21473. Epub 2014 Aug 12.

34.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

35.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

36.

Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabuddhe VV, Chen J, Lorey TS, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Castle PE.

J Clin Microbiol. 2014 Aug;52(8):2892-7. doi: 10.1128/JCM.03517-13. Epub 2014 Jun 4.

37.

Neonatal total bilirubin measurements: Still room for harmonization.

Greene DN, Liang J, Holmes DT, Resch A, Lorey TS.

Clin Biochem. 2014 Aug;47(12):1112-5. doi: 10.1016/j.clinbiochem.2014.04.001. Epub 2014 Apr 13.

PMID:
24731789
38.

Falsely undetectable TSH in a cohort of South Asian euthyroid patients.

Drees JC, Stone JA, Reamer CR, Arboleda VE, Huang K, Hrynkow J, Greene DN, Petrie MS, Hoke C, Lorey TS, Dlott RS.

J Clin Endocrinol Metab. 2014 Apr;99(4):1171-9. doi: 10.1210/jc.2013-2092. Epub 2013 Jan 1.

PMID:
24423284
39.

Development of an equation to correct for hemolysis in direct bilirubin measurements.

Greene DN, Holmes DT, Lin MJ, Liang JY, Lorey TS, Schmidt RL.

Clin Chim Acta. 2014 Feb 15;429:194-7. doi: 10.1016/j.cca.2013.12.023. Epub 2013 Dec 27.

PMID:
24373895
40.

Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.

Dinkelspiel H, Fetterman B, Poitras N, Kinney W, Cox JT, Lorey T, Castle PE.

J Low Genit Tract Dis. 2014 Jan;18(1):57-60. doi: 10.1097/LGT.0b013e31829325c3.

PMID:
24022057
41.

Performance specifications of common chemistry analytes on the AU series of chemistry analyzers for miscellaneous body fluids.

Lin MJ, Hoke C, Dlott R, Lorey TS, Greene DN.

Clin Chim Acta. 2013 Nov 15;426:121-6. doi: 10.1016/j.cca.2013.08.011. Epub 2013 Aug 24.

PMID:
23981843
42.

Identification of one or two α-globin gene deletions by isoelectric focusing electrophoresis.

Agarwal AM, Nussenzveig RH, Hoke C, Lorey TS, Greene DN.

Am J Clin Pathol. 2013 Sep;140(3):301-5. doi: 10.1309/AJCPF4UIJKH3EOBY.

PMID:
23955447
43.

Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men.

Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabuddhe VV, Luhn P, Gage JC, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Dec 1;208(11):1768-75. doi: 10.1093/infdis/jit374. Epub 2013 Aug 1.

44.

Risk of cervical precancer and cancer in women with cervical intraepithelial neoplasia grade 1 on endocervical curettage.

Fukuchi E, Fetterman B, Poitras N, Kinney W, Lorey T, Littell RD.

J Low Genit Tract Dis. 2013 Jul;17(3):255-60. doi: 10.1097/LGT.0b013e31826ca4d9.

PMID:
23733162
45.

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.

46.

Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.

Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

47.

Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S64-8. doi: 10.1097/LGT.0b013e3182854399.

48.

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S56-63. doi: 10.1097/LGT.0b013e318285437b.

49.

Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S50-5. doi: 10.1097/LGT.0b013e3182854282.

50.

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S43-9. doi: 10.1097/LGT.0b013e3182854269.

Supplemental Content

Support Center